SEC Form 4 · accession 0001179110-18-006501
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael G Howley
Officer — VP, Global Sales & Marketing
Period of report
May 7, 2018
Accepted (ET)
May 9, 2018 · 7:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par valueF5 | May 7, 2018 | M | 17,500 | $21.55 | A | 64,257 | D | |
| Common Stock, $.01 par valueF6,F7 | May 7, 2018 | S | 800 | $345.085 | D | 63,457 | D | |
| Common Stock, $.01 par valueF6,F8 | May 7, 2018 | S | 2,551 | $346.1299 | D | 60,906 | D | |
| Common Stock, $.01 par valueF6,F9 | May 7, 2018 | S | 4,101 | $347.0319 | D | 56,805 | D | |
| Common Stock, $.01 par valueF6,F10 | May 7, 2018 | S | 2,100 | $348.0595 | D | 54,705 | D | |
| Common Stock, $.01 par valueF6,F11 | May 7, 2018 | S | 5,236 | $349.0837 | D | 49,469 | D | |
| Common Stock, $.01 par valueF6,F12 | May 7, 2018 | S | 1,312 | $350.0159 | D | 48,157 | D | |
| Common Stock, $.01 par valueF6,F13 | May 7, 2018 | S | 1,000 | $350.876 | D | 47,157 | D | |
| Common Stock, $.01 par valueF6 | May 7, 2018 | S | 200 | $351.97 | D | 46,957 | D | |
| Common Stock, $.01 par valueF6 | May 7, 2018 | S | 200 | $352.78 | D | 46,757 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $21.55 | May 7, 2018 | M | 17,500 | D | May 14, 2015 | May 14, 2024 | Common Stock | 17,500 | 7,500 | D |
| Stock Option (Right to Buy)F1,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 25,000 | D |
| Stock Option (Right to Buy)F1,F3 | $66.25 | holding | — | — | — | May 13, 2016 | May 13, 2025 | Common Stock | 0 | 5,000 | D |
| Stock Option (Right to Buy)F4,F3 | $99.62 | holding | — | — | — | May 24, 2017 | May 24, 2026 | Common Stock | 0 | 8,000 | D |
| Stock Option (Right to Buy)F4,F3 | $134.51 | holding | — | — | — | May 15, 2018 | May 15, 2027 | Common Stock | 0 | 6,500 | D |
Explanation of responses
- F1Grant to reporting person of option to buy the number of shares of common stock set forth on Table II, Column 7, under the Abiomed, Inc. 2008 Stock Incentive Plan.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $347.6500 and $348.5300. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F11This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $348.6800 and $349.4500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F12This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $349.6600 and $350.4100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F13This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $350.7100 and $350.9800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2These options become exerciseable in annual 25% increments, commencing on the date shown forth in Table II, Column 6.
- F3These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F4Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- F5Exercise of stock options pursuant to reporting owner's 10b5-1 plan.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $344.5600 and $345.4700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $345.6100 and $346.5500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $346.5600 and $347.5500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.